Xiao-yan Ma
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A.
Journal: Cancer letters
Published: March 04, 2024
Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.
Journal: Cell biology and toxicology
Published: December 31, 2023
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer.
Journal: Cancer research
Published: September 14, 2023
ETHE1 Accelerates Triple-Negative Breast Cancer Metastasis by Activating GCN2/eIF2α/ATF4 Signaling.
Journal: International journal of molecular sciences
Published: July 12, 2023
Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
Journal: Theranostics
Published: October 09, 2022
Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Journal: Cancer research
Published: August 26, 2022
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Journal: Molecular cancer
Published: January 13, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 05, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026